31449560|t|Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
31449560|a|OBJECTIVE: To compare effectiveness and safety of warfarin and the direct oral anticoagulants (DOAC) dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation in routine care. METHODS: From nationwide registries, we identified treatment-naive patients initiating warfarin, dabigatran, rivaroxaban or apixaban for non-valvular atrial fibrillation from July 2013 to December 2015 in Norway. We assessed prescription duration using reverse waiting time distribution. Adjusting for confounding in a Cox proportional hazards model, we estimated one-year risks for ischemic stroke, transient ischemic attack (TIA) or systemic embolism, major or clinically relevant non-major bleeding; intracranial; gastrointestinal; and other bleeding. We censored at switch of treatment or 365 days of follow-up. RESULTS: We included 30,820 treatment-naive patients. Compared to warfarin, the adjusted hazard ratios (HR) for ischemic stroke, TIA or systemic embolism were 0.96 (95% CI 0.71-1.28) for dabigatran, 1.12 (95% CI 0.87-1.45) for rivaroxaban and 0.97 (95% CI 0.75-1.26) for apixaban. Corresponding hazard ratios for major or clinically relevant non-major bleeding were 0.73 (95% CI 0.62-0.86) for dabigatran, 0.97 (95% CI 0.84-1.12) for rivaroxaban and 0.71 (95% CI 0.62-0.82) for apixaban. Statistically significant differences of other safety outcomes compared to warfarin were fewer intracranial bleedings with dabigatran (HR 0.28, 95% CI 0.14-0.56), rivaroxaban (HR 0.40, 95% CI 0.23-0.69) and apixaban (HR 0.56, 95% CI 0.34-0.92); fewer gastrointestinal bleedings with apixaban (HR 0.70, 95% CI 0.52-0.93); and fewer other bleedings with dabigatran (HR 0.67, 95% CI 0.55-0.81) and apixaban (HR 0.70, 95% CI 0.59-0.83). CONCLUSION: After 1 year follow-up in treatment-naive patients initiating oral anticoagulation for non-valvular atrial fibrillation, all DOACs were similarly effective as warfarin in prevention of ischemic stroke, TIA or systemic embolism. Safety from bleedings was similar or better, including fewer intracranial bleedings with all direct oral anticoagulants, fewer gastrointestinal bleedings with apixaban and fewer other bleedings with dabigatran and apixaban.
31449560	29	37	warfarin	Chemical	MESH:D014859
31449560	39	49	dabigatran	Chemical	MESH:D000069604
31449560	51	62	rivaroxaban	Chemical	MESH:D000069552
31449560	67	75	apixaban	Chemical	MESH:C522181
31449560	92	111	atrial fibrillation	Disease	MESH:D001281
31449560	207	215	warfarin	Chemical	MESH:D014859
31449560	224	250	direct oral anticoagulants	Chemical	-
31449560	252	256	DOAC	Chemical	-
31449560	258	268	dabigatran	Chemical	MESH:D000069604
31449560	270	281	rivaroxaban	Chemical	MESH:D000069552
31449560	286	294	apixaban	Chemical	MESH:C522181
31449560	311	330	atrial fibrillation	Disease	MESH:D001281
31449560	415	423	patients	Species	9606
31449560	435	443	warfarin	Chemical	MESH:D014859
31449560	445	455	dabigatran	Chemical	MESH:D000069604
31449560	457	468	rivaroxaban	Chemical	MESH:D000069552
31449560	472	480	apixaban	Chemical	MESH:C522181
31449560	498	517	atrial fibrillation	Disease	MESH:D001281
31449560	731	746	ischemic stroke	Disease	MESH:D002544
31449560	748	773	transient ischemic attack	Disease	MESH:D002546
31449560	775	778	TIA	Disease	MESH:D002546
31449560	783	800	systemic embolism	Disease	MESH:D004617
31449560	841	849	bleeding	Disease	MESH:D006470
31449560	851	863	intracranial	Disease	MESH:D001932
31449560	865	881	gastrointestinal	Disease	MESH:D005767
31449560	893	901	bleeding	Disease	MESH:D006470
31449560	1008	1016	patients	Species	9606
31449560	1030	1038	warfarin	Chemical	MESH:D014859
31449560	1076	1091	ischemic stroke	Disease	MESH:D002544
31449560	1093	1096	TIA	Disease	MESH:D002546
31449560	1100	1117	systemic embolism	Disease	MESH:D004617
31449560	1151	1161	dabigatran	Chemical	MESH:D000069604
31449560	1191	1202	rivaroxaban	Chemical	MESH:D000069552
31449560	1235	1243	apixaban	Chemical	MESH:C522181
31449560	1316	1324	bleeding	Disease	MESH:D006470
31449560	1358	1368	dabigatran	Chemical	MESH:D000069604
31449560	1398	1409	rivaroxaban	Chemical	MESH:D000069552
31449560	1442	1450	apixaban	Chemical	MESH:C522181
31449560	1527	1535	warfarin	Chemical	MESH:D014859
31449560	1547	1569	intracranial bleedings	Disease	MESH:D013345
31449560	1575	1585	dabigatran	Chemical	MESH:D000069604
31449560	1615	1626	rivaroxaban	Chemical	MESH:D000069552
31449560	1659	1667	apixaban	Chemical	MESH:C522181
31449560	1703	1729	gastrointestinal bleedings	Disease	MESH:D006471
31449560	1735	1743	apixaban	Chemical	MESH:C522181
31449560	1789	1798	bleedings	Disease	MESH:D006470
31449560	1804	1814	dabigatran	Chemical	MESH:D000069604
31449560	1847	1855	apixaban	Chemical	MESH:C522181
31449560	1939	1947	patients	Species	9606
31449560	1997	2016	atrial fibrillation	Disease	MESH:D001281
31449560	2022	2027	DOACs	Chemical	-
31449560	2056	2064	warfarin	Chemical	MESH:D014859
31449560	2082	2097	ischemic stroke	Disease	MESH:D002544
31449560	2099	2102	TIA	Disease	MESH:D002546
31449560	2106	2123	systemic embolism	Disease	MESH:D004617
31449560	2137	2146	bleedings	Disease	MESH:D006470
31449560	2186	2208	intracranial bleedings	Disease	MESH:D013345
31449560	2218	2244	direct oral anticoagulants	Chemical	-
31449560	2252	2278	gastrointestinal bleedings	Disease	MESH:D006471
31449560	2284	2292	apixaban	Chemical	MESH:C522181
31449560	2309	2318	bleedings	Disease	MESH:D006470
31449560	2324	2334	dabigatran	Chemical	MESH:D000069604
31449560	2339	2347	apixaban	Chemical	MESH:C522181
31449560	Comparison	MESH:D000069604	MESH:D014859
31449560	Negative_Correlation	MESH:C522181	MESH:D006471
31449560	Negative_Correlation	MESH:D000069604	MESH:D002544
31449560	Negative_Correlation	MESH:C522181	MESH:D004617
31449560	Negative_Correlation	MESH:C522181	MESH:D002544
31449560	Comparison	MESH:C522181	MESH:D014859
31449560	Negative_Correlation	MESH:D000069552	MESH:D001281
31449560	Negative_Correlation	MESH:C522181	MESH:D001281
31449560	Negative_Correlation	MESH:D000069552	MESH:D004617
31449560	Negative_Correlation	MESH:D000069604	MESH:D004617
31449560	Negative_Correlation	MESH:D000069604	MESH:D002546
31449560	Positive_Correlation	MESH:C522181	MESH:D006470
31449560	Negative_Correlation	MESH:D000069552	MESH:D002544
31449560	Negative_Correlation	MESH:D000069552	MESH:D002546
31449560	Negative_Correlation	MESH:C522181	MESH:D002546
31449560	Positive_Correlation	MESH:D000069552	MESH:D006470
31449560	Comparison	MESH:D000069552	MESH:D014859
31449560	Negative_Correlation	MESH:D000069604	MESH:D006470
31449560	Comparison	MESH:C522181	MESH:D000069604
31449560	Negative_Correlation	MESH:D000069604	MESH:D001281
31449560	Comparison	MESH:C522181	MESH:D000069552
31449560	Negative_Correlation	MESH:D000069604	MESH:D013345
31449560	Negative_Correlation	MESH:C522181	MESH:D013345
31449560	Negative_Correlation	MESH:D014859	MESH:D001281
31449560	Negative_Correlation	MESH:D014859	MESH:D002546
31449560	Negative_Correlation	MESH:D000069552	MESH:D013345
31449560	Comparison	MESH:D000069552	MESH:D000069604
31449560	Positive_Correlation	MESH:D014859	MESH:D006471

